Description
Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. It works by activating both receptors to increase levels of hormones that regulate appetite and blood sugar, helping you feel fuller for longer after meals.
Tirzepatide is administered as a once-weekly self-injection alongside a reduced-calorie diet and increased physical activity. Depending on your region and clinical assessment, tirzepatide may be licensed for type 2 diabetes management, chronic weight management, or both.
Mounjaro is a prescription-only medicine. Eligibility is assessed through a medical questionnaire reviewed by our clinical team, and a prescription is issued only where it is clinically appropriate for you. Dosing is increased gradually under clinical guidance to help manage side effects such as nausea. Do not start, stop, or change your dose without direction from your prescriber.
Reviews
There are no reviews yet.